EKARIN APIRAKTHANAKORN / SHUTTERSTOCK.COM
Non-profit organisation I-MAK is attempting to expose the problem at the heart of the patent system—that too often drug patents are wrongfully granted and consequently sick people in poorer countries are being left untreated. LSIPR delves deeper into the issues.
The 2013 film “Dallas Buyers Club” touched many with its story about HIV/AIDS. So powerful was the account of Ron Woodroof’s attempt to bring affordable drugs to AIDS patients in Texas that the film generated critical acclaim.
Woodroof’s story resonates today. In August, a former student called Greg Jefferys compared himself to the Texan in an article published by the Australian Broadcasting Corporation. He began importing Sovaldi (sofosbuvir) from Chennai in India to Australia, as he argued the drug was more affordable in the Asian country.
Central to both Woodroof’s and Jefferys’ story is the quest to bring affordable drugs to market for people who desperately need them. In a similar fashion, US-based not-for-profit organisation the Initiative for Medicines, Access & Knowledge (I-MAK) has opposed one of two patent applications for Gilead’s drug Sovaldi on the grounds it is invalid. What motivates I-MAK, which has filed challenges in several jurisdictions, is a drive to bring down the cost of Sovaldi, a treatment for people suffering with hepatitis C.
You need a subscription to continue reading this content.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
News stories up to a week old and feature articles on the day of publication are accessible with a BASIC FREE ACCOUNT.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’; and for basic access to the latest news on the website and weekly email news alerts choose the 'BASIC FREE ACCOUNT' registration.
HIV/AIDS, Solvadi, EPO, SIPO. I-MAK, Solvadi, patent, patent licensing, Gilead